RE:RE:RE:RE:RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….Nothing I post is made up.
They have applied for an FDA meeting for a MBc phase 3 trial details.
They did recieve positive data adding enrolment with the Roche goblet anal cancer arm
The did recieve approval from PanCan to proceed with the pancreatic cancer precicion promise trial.
Then it was cancelled due to PanCan closing down ALl of the precicion promise programs.
That event did damage the shareprice.
On the plus, they did continue with the $5 million grant.
Onc does have two ongoing phase 3 potential FDA fast track designations. One for pancreatic & the other for MBc.
The anal cancer trial showed strong enough. Data to move forward with increased enrolment.
They do have two upcoming presentation at ASCO. That information is vague, but they would not invest time & money to showcase failures.
So far everything I have posted is 100% factual. Publicly reported & peer reviewed.
Regarding partership, buyouts or similar?
I appreciate Bucky can not read beyind grade 5 level. But have someone read to you. All of my " predictions" have been clearly defined as such.Predictions & speculations defined as such are just that.
A question was asked about the process & liklyhood of announcements coming up.
My answer while lenghly explained the process ...even as far as to say, nobody knows what is going on.
We will only know if/ when there is an announcement.
As far as knowing about bucky.
i know you are uneducated, rude, and only have ever posted negative comments.
Onc has come a long way in the past 12 months.
The share price does not reflect that at all.
when that massive imbalance happens, 3 options.
1. The news catches up & refects the dismal price.
2. The price recovers. Which it has been doing very slowly. Very very slowly.
3. The company is bought out.
The trading refects a wait & see approach.
So we wait & see.